| 1919 |
Foundation
of the Laboratorio Experimental de Terapéutica Inmunógena (LETI) in
Barcelona (Spain). |
| 1941 |
Creation
of the LETI Allergy Service as a natural development within a company clearly devoted
to immunology from its foundation. |
| 1949 |
Foundation of the Spanish Society of Allergy with Dr. Ramón Surinyach-Oller (Director of the LETI Allergy Service) as founding member. Dr. Surinyach closes the first conference of the Spanish Society of Allergy, held the same year, with the lecture “Unification of techniques for the study of the botanical conditions in relation to asthma in Spain”. |
| 1969 |
Dr.
Surinyach becomes President of the Spanish Society of Allergy. |
| 1984 |
Allergy
becomes the core of LETI commercial and research activity. |
| 1985 |
Creation
of the Corporación Biológica Farmacéutica (CBF) as a research
unit in allergy. |
| 1990 |
Launch
of the product line Alergoide Retard. First world manufacturer to obtain a polymerised
allergen extract from mites as raw material. |
| 1992 |
Inauguration
of the R&D laboratory and production plant in Tres Cantos, Madrid. |
| 1994 |
Launch
of the TOL line. Allergen extracts for sublingual administration. |
| 1995 |
LETI
becomes the only Spanish member of the European Allergen Manufacturers Group (EAMG). |
| 1996 |
LETI
becomes the first Spanish immunotherapy manufacturer to obtain ISO 9002 certification.
|
| 1997 |
LETI begins its commercial activities in Chile |
| 1999 |
LETI
becomes a founding member of the Spanish Association of Biocompanies (ASEBIO). |
| 2000 |
Launch
of the Depigoid line. Depigmented allergen extracts polymerised with glutaraldehyde
and adsorbed to aluminum hydroxide.
Creation
of LETI Pharma GmbH and initiation of sales of allergenic extracts in Germany.
|
| 2001 |
Registration of the first allergen extracts for diagnostic purposes in the Paul Ehrlich
Institut (Germany).
LETI initiates the sale of allergen extracts in South Africa. |
| 2004 |
LETI begins to sell its allergen extracts in Colombia. |
| 2005 |
It is obtained drug licensing approval in the Paul Ehrlich Institut (Germany) for the treatment of respiratory allergy (rhinoconjunctivitis and asthma) in patients who are sensitive to mites.
Initiation of sales of LETI products in Mexico. |
